File Download
  Links for fulltext
     (May Require Subscription)

Article: Up-regulation of microRNAs, miR21 and miR23a in human liver cancer cells treated with Coptidis rhizoma aqueous extract

TitleUp-regulation of microRNAs, miR21 and miR23a in human liver cancer cells treated with Coptidis rhizoma aqueous extract
Authors
KeywordsCoptidis rhizoma aqueous extract
Hepatocellular carcinoma
MicroRNA
miR-21
miR-23a
Issue Date2011
PublisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com
Citation
Experimental And Therapeutic Medicine, 2011, v. 2 n. 1, p. 27-32 How to Cite?
Abstract
Coptidis rhizoma (CR; Huanglian in Chinese) has been used for the treatment of cancer in Chinese medicine, and recent studies have supported its use in cancer therapy. MicroRNAs (miRNAs) play an important role in the pathophysiology of human cancers. We examined alterations in the miRNA profile of hepatocellular carcinoma (HCC) cells after treatment with coptidis rhizoma aqueous extract (CRAE). An on-chip microarray method was used to detect alterations in the expression profile of miRNAs in human HCCMHCC97-Lcells after exposure to 175 μg/ml CRAE. Altered expression of several miRNAs was detected in the MHCC97-Lcells after treatment with 175 μg/ml CRAE. The microarray results were validated by quantitative real-time PCR(qRT-PCR). Consistent results were obtained; qRT-PCR confirmed that both miR-21 and miR-23a were significantly up-regulated. TargetScan and PicTar microRNA databases were used to predict the possible target genes of the altered miRNAs. The results showed that the altered miRNAs after CRAE treatment may serve as markers for the therapy of liver cancer. To the best of our knowledge, this is the first report on the up-regulation of miRNAs, miR21 and miR23a in human liver cancer cells treated with CRAE. Our results suggest that CRAE targets miR-21 and miR-23a in liver cancer cells supporting the potential application of CRAE in the treatment of HCC.
Persistent Identifierhttp://hdl.handle.net/10722/138139
ISSN
2013 Impact Factor: 0.941
ISI Accession Number ID
Funding AgencyGrant Number
research council of the University of Hong Kong200907176140
Research Grants Council (RGC) of Hong Kong SAR, China764708M
Pong Ding Yueng Endowment Fund for Education and Research in Chinese-Western Medicine20005274
Hong Kong Government20740314
Funding Information:

The present study was financially supported by grants from the research council of the University of Hong Kong (project code, 200907176140), the Research Grants Council (RGC) of Hong Kong SAR, China (project code, 764708M), the Pong Ding Yueng Endowment Fund for Education and Research in Chinese-Western Medicine (project code, 20005274) and the Hong Kong Government-Matching Grant Scheme (4th Phase, project code, 20740314). The cell line MHCC97-L was a kind gift from the Liver Cancer Institute Fudan University, Shanghai, China. The authors would like to express thanks to Dr Ka-Yu Siu, Ms. Cindy Lee, Mr. Keith Wong and Mr. Freddy Tsang for the technical support.

References

 

Author Affiliations
  1. School of Chinese Medicine
  2. The University of Hong Kong
  3. Sun Yat-Sen University
DC FieldValueLanguage
dc.contributor.authorZhu, Men_HK
dc.contributor.authorWang, Nen_HK
dc.contributor.authorTsao, SWen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorFeng, Yen_HK
dc.contributor.authorWan, TSKen_HK
dc.contributor.authorMan, Ken_HK
dc.contributor.authorFeng, Yen_HK
dc.date.accessioned2011-08-26T14:41:21Z-
dc.date.available2011-08-26T14:41:21Z-
dc.date.issued2011en_HK
dc.identifier.citationExperimental And Therapeutic Medicine, 2011, v. 2 n. 1, p. 27-32en_HK
dc.identifier.issn1792-0981en_HK
dc.identifier.urihttp://hdl.handle.net/10722/138139-
dc.description.abstractCoptidis rhizoma (CR; Huanglian in Chinese) has been used for the treatment of cancer in Chinese medicine, and recent studies have supported its use in cancer therapy. MicroRNAs (miRNAs) play an important role in the pathophysiology of human cancers. We examined alterations in the miRNA profile of hepatocellular carcinoma (HCC) cells after treatment with coptidis rhizoma aqueous extract (CRAE). An on-chip microarray method was used to detect alterations in the expression profile of miRNAs in human HCCMHCC97-Lcells after exposure to 175 μg/ml CRAE. Altered expression of several miRNAs was detected in the MHCC97-Lcells after treatment with 175 μg/ml CRAE. The microarray results were validated by quantitative real-time PCR(qRT-PCR). Consistent results were obtained; qRT-PCR confirmed that both miR-21 and miR-23a were significantly up-regulated. TargetScan and PicTar microRNA databases were used to predict the possible target genes of the altered miRNAs. The results showed that the altered miRNAs after CRAE treatment may serve as markers for the therapy of liver cancer. To the best of our knowledge, this is the first report on the up-regulation of miRNAs, miR21 and miR23a in human liver cancer cells treated with CRAE. Our results suggest that CRAE targets miR-21 and miR-23a in liver cancer cells supporting the potential application of CRAE in the treatment of HCC.en_HK
dc.languageengen_US
dc.publisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com en_HK
dc.relation.ispartofExperimental and Therapeutic Medicineen_HK
dc.subjectCoptidis rhizoma aqueous extracten_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectMicroRNAen_HK
dc.subjectmiR-21en_HK
dc.subjectmiR-23aen_HK
dc.titleUp-regulation of microRNAs, miR21 and miR23a in human liver cancer cells treated with Coptidis rhizoma aqueous extracten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1792-0981&volume=2&issue=1&spage=27&epage=32&date=2011&atitle=Up-regulation+of+microRNAs,+miR21+and+miR23a,+in+human+liver+cancer+cells+treated+with+Coptidis+rhizome+aqueous+extract-
dc.identifier.emailTsao, SW: gswtsao@hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.emailMan, K: kwanman@hku.hken_HK
dc.identifier.emailFeng, Y: yfeng@hku.hken_HK
dc.identifier.authorityTsao, SW=rp00399en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityMan, K=rp00417en_HK
dc.identifier.authorityFeng, Y=rp00466en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.3892/etm.2010.164-
dc.identifier.scopuseid_2-s2.0-78751622851en_HK
dc.identifier.hkuros191223en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78751622851&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume2en_HK
dc.identifier.issue1en_HK
dc.identifier.spage27en_HK
dc.identifier.epage32en_HK
dc.identifier.isiWOS:000286365000004-
dc.publisher.placeGreeceen_HK
dc.identifier.scopusauthoridZhu, M=36706949300en_HK
dc.identifier.scopusauthoridWang, N=35072317700en_HK
dc.identifier.scopusauthoridTsao, SW=7102813116en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridFeng, Y=36983738700en_HK
dc.identifier.scopusauthoridWan, TSK=25623981600en_HK
dc.identifier.scopusauthoridMan, K=7101754072en_HK
dc.identifier.scopusauthoridFeng, Y=24467969600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats